Vascular calcification in patients with chronic kidney disease: Types, clinical impact and pathogenesis

Medical Principles and Practice

Volumn 20, Issue 3, 2011, Pages 203-212

  Román García, Pablo ^a   Rodríguez García, Minerva ^a   Cabezas Rodríguez, Iván ^a   López Ongil, Susana ^b   Díaz López, Bernardino ^a   Cannata Andía, Jorge B ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Bone loss vascular bone links; Chronic kidney disease; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; FETUIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; KLOTHO PROTEIN; LANTHANUM CARBONATE; OSTEOPROTEGERIN; PHOSPHORUS; PYROPHOSPHATE; SEVELAMER; SEVELAMER CARBONATE; TECALCET; TRANSCRIPTION FACTOR MSX2; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE; WNT PROTEIN;

ALBUMIN BLOOD LEVEL; ALCOHOL ABSTINENCE; ANEMIA; ARTERY CALCIFICATION; ARTERY DIAMETER; BLOOD PRESSURE REGULATION; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSLIPIDEMIA; FAMILY HISTORY; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERHOMOCYSTEINEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPARATHYROIDISM; ISCHEMIC HEART DISEASE; LOW FAT DIET; MALNUTRITION; MOLECULAR BIOLOGY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOLOGIC FRACTURE; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; SENESCENCE; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION; SODIUM RESTRICTION; UREMIA; VITAMIN SUPPLEMENTATION;

CALCIFICATION, PHYSIOLOGIC; CALCINOSIS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY DISEASES; RISK FACTORS; VASCULAR DISEASES;

EID: 79953651744     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323434     Document Type: Review

References (101)

1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
2. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314. (Pubitemid 39302630)
3. Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
4. Micheletti RG, Fishbein GA, Currier JS, Singer EJ, Fishbein MC: Calcification of the internal elastic lamina of coronary arteries. Mod Pathol 2008; 21: 1019-1028.
5. McCullough PA, Agrawal V, Danielewicz E, Abela GS: Accelerated atherosclerotic calcification and monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585-1598.
6. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126. (Pubitemid 29054847)
7. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874. (Pubitemid 36019640)
8. Sessa R, Cipriani P, Di Pietro M, Schiavoni G, Santino I, Del Piano M: Chlamydia pneumonia and chronic diseases with a great impact on public health. Int J Immunopathol Pharmacol 2008; 21: 1041-1043.
9. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P: Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007; 27(suppl 2):S205-S209. (Pubitemid 350047702)
10. Doherty TM, Fitzpatrick LA, Shaheen A, Rajavashisth TB, Detrano RC: Genetic determinants of arterial calcification associated with atherosclerosis. Mayo Clin Proc 2004; 79: 197-210. (Pubitemid 38140804)
11. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B: Vascular calcifications: Pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006; 17:S267-273. (Pubitemid 44865260)
12. Roman-Garcia P, Carrillo-Lopez N, Cannata- Andia JB: Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia. J Ren Care 2009; 35(suppl 1):34-38.
13. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37-43. (Pubitemid 27395339)
14. Mazzaferro S, Coen G, Bandini S, Borgatti PP, Ciaccheri M, Diacinti D, Ferranti E, Lusenti T, Mancini G, Monducci I, et al: Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 1993; 8: 335-340. (Pubitemid 23129901)
15. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR: Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2: 875-877. (Pubitemid 17154752)
16. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483. (Pubitemid 30318271)
17. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
18. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with crf not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030. (Pubitemid 39556482)
19. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513. (Pubitemid 41725148)
20. Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andia JB: Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 239-246.
21. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E: Artery-related differences in atherosclerosis expression: Implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007; 38: 2698-2705. (Pubitemid 47494006)
22. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037-2040. (Pubitemid 28356772)
23. Okuda K, Kobayashi S, Hayashi H, Ohtake H, Nakajima Y, Yoshida K, Kashima H, Irie Y: Case-control study of calcification of the hepatic artery in chronic hemodialysis patients: comparison with the abdominal aorta and splenic artery. J Gastroenterol Hepatol 2002; 17: 91-95. (Pubitemid 34304393)
24. Yuen D, Pierratos A, Richardson RM, Chan CT: The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1407-1412.
25. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W: Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22: 515-521. (Pubitemid 46193946)
26. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529-1534. (Pubitemid 32226260)
27. Goldsmith D, Ritz E, Covic A: Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66: 1315-1333. (Pubitemid 39298364)
28. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951. (Pubitemid 38822076)
29. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis study. J Bone Miner Res 1996; 11: 1010-1018. (Pubitemid 26200053)
30. Naves Diaz M, Diaz Lopez JB, Gomez Alonso C, Altadill Arregui A, Rodriguez Rebollar A, Cannata Andia JB: Study of incidence of osteoporotic fractures in a cohort of individuals older than 50 years from Asturias, Spain, after a 6 year follow-up period. Med Clin (Barc) 2000; 115: 650-653. (Pubitemid 33607596)
31. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham heart study. Calcif Tissue Int 2001; 68: 271-276. (Pubitemid 32565728)
32. Naves Diaz M, Diaz Lopez JB, Gomez C, Rodriguez Rebollar A, Rodriguez Garcia M, Cannata Andia JB: Association between current bone metabolism parameters and the progression of vascular calcification in men and women. J Bone Miner Res 2004; 19: S-365.
33. Frye MA, Melton LJ, 3rd, Bryant SC, Fitzpatrick LA, Wahner HW, Schwartz RS, Riggs BL: Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-194.
34. Voigt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA: Bone mineral density and aortic calcification: the study of osteoporotic fractures. J Am Geriatr Soc 1997; 45: 140-145. (Pubitemid 27066521)
35. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-Alonso C, Cannata-Andia JB: Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008; 19: 1161-1166.
36. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 4246-4253. (Pubitemid 39244420)
37. Qunibi WY: Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16 (suppl 2):S95-102.
38. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701. (Pubitemid 29159935)
39. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in longterm experimental uremia. Kidney Int 2003; 64: 1653-1661. (Pubitemid 37323693)
40. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
41. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965. (Pubitemid 351697566)
42. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Phosphate binder impact on bone remodeling and coronary calcification - results from the BRIC study. Nephron Clin Pract 2008; 110:c273-283.
43. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
44. Naves-Diaz M, Alvarez-Hernandez D, Passlick- Deetjen J, Guinsburg A, Marelli C, Rodriguez- Puyol D, Cannata-Andia JB: Oral active vitamin d is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
45. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125. (Pubitemid 41710323)
46. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M: Calcimimetic r-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
47. Lopez I, Mendoza FJ, Guerrero F, Almaden Y, Henley C, Aguilera-Tejero E, Rodriguez M: The calcimimetic AMG 641 accelerates regression of extraosseous calcifications in uremic rats. Am J Physiol Renal Physiol 2009; 296:F1376-F1385.
48. Budoff MJ, Lane KL, Bakhsheshi H, Mao S, Grassmann BO, Friedman BC, Brundage BH: Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol 2000; 86: 8-11. (Pubitemid 30365135)
49. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972-1978. (Pubitemid 29024129)
50. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001; 38: 64-69. (Pubitemid 32611760)
51. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
52. Ishimura E, Okuno S, Taniwaki H, Kizu A, Tsuchida T, Shioi A, Shoji T, Tabata T, Inaba M, Nishizawa Y: Different risk factors for vascular calcification in end-stage renal disease between diabetics and nondiabetics: the respective importance of glycemic and phosphate control. Kidney Blood Press Res 2008; 31: 10-15. (Pubitemid 351310029)
53. Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y: Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients - importance of glycaemic control. Diabetologia 2002; 45: 1446-1448. (Pubitemid 35244899)
54. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
55. Holden RM, Booth SL: Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007; 3: 522-523. (Pubitemid 47482715)
56. Persy V, De Broe M, Ketteler M: Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 2006; 70: 1537-1538. (Pubitemid 44606986)
57. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H: Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259. (Pubitemid 46233170)
58. Neven EG, De Broe ME, D'Haese PC: Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 2009; 75: 580-582.
59. Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824. (Pubitemid 32448773)
60. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H: Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688. (Pubitemid 39237612)
61. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC: Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-625.
62. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008; 73: 384-390. (Pubitemid 351186286)
63. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216. (Pubitemid 351240642)
64. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964. (Pubitemid 39578826)
65. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen- Dechent W, Weissberg PL, Shanahan CM: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867. (Pubitemid 41103395)
66. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE: Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: 20-28.
67. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R: Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-157. (Pubitemid 351915080)
68. Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB: Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol 2005; 18: 458-463. (Pubitemid 41700114)
69. Li X, Yang HY, Giachelli CM: Role of the sodium- dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912.
70. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
71. Mizobuchi M, Ogata H, Hatamura I, Koiwa F, Saji F, Shiizaki K, Negi S, Kinugasa E, Ooshima A, Koshikawa S, Akizawa T: Upregulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant 2006; 21: 911-916.
72. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA: Aortic Msx2-Wnt calcification cascade is regulated by TNF-α -dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-2596. (Pubitemid 350158910)
73. Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP: Osteogenic regulation of vascular calcification. Ann NY Acad Sci 2006; 1068: 327-333. (Pubitemid 43824164)
74. Roman-Garcia P, Carrillo-Lopez N, Fernandez- Martin JL, Naves-Diaz M, Ruiz-Torres MP, Cannata-Andia JB: High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128.
75. Shao JS, Cheng SL, Pingsterhaus JM, Charlton- Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine wnt signals. J Clin Invest 2005; 115: 1210-1220. (Pubitemid 40629039)
76. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y: Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by Akt signaling. J Biol Chem 2008; 283: 15319-15327.
77. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr., Pomerantzeff PM, Laurindo FR: Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008; 28: 463-470.
78. Oberg BP, McMenamin E, Lucas FL, Mc- Monagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016. (Pubitemid 38251077)
79. Johnson K, Polewski M, van Etten D, Terkeltaub R: Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005; 25: 686-691. (Pubitemid 40463854)
80. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nurnberg P: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34: 379-381. (Pubitemid 36935330)
81. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW: Regulation of osteogenesis by fetuin. J Biol Chem 1999; 274: 28514-28520.
82. Westenfeld R, Jahnen-Dechent W, Ketteler M: Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007; 17: 124-128. (Pubitemid 46670022)
83. Merx MW, Schafer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 2005; 16: 3357-3364. (Pubitemid 46179339)
84. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268. (Pubitemid 28213402)
85. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, Mito S, Soe NN, Yoshizumi M: Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol 2007; 27: 2058-2064. (Pubitemid 47312318)
86. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009; 104: 1041-1048.
87. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51. (Pubitemid 27494749)
88. Memon F, El-Abbadi M, Nakatani T, Taguchi T, Lanske B, Razzaque MS: Does Fgf23- klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? Kidney Int 2008;74: 566-570.
89. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833. (Pubitemid 41325087)
90. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006; 281: 6120-6123. (Pubitemid 43847540)
91. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008. (Pubitemid 350224109)
92. Torres PU, Prie D, Molina-Bletry V, Beck L, Silve C, Friedlander G: Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007; 71: 730-737. (Pubitemid 46624027)
93. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. (Pubitemid 32156196)
94. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
95. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605. (Pubitemid 44199649)
96. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T: Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1013-1019. (Pubitemid 351398587)
97. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2380-2386.
98. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T: Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 2008; 26: 93-100. (Pubitemid 350307997)
99. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP: Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001; 28: 195-201. (Pubitemid 32140975)
100. Tang SY, Zeenath U, Vashishth D: Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007; 40: 1144-1151. (Pubitemid 46386561)
101. Franke S, Siggelkow H, Wolf G, Hein G: Advanced glycation endproducts influence the mrna expression of rage, rankl and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007; 113: 154-161. (Pubitemid 47547388)